Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Implementing an Integrated Pharmaceutical Management Information System for Antiretrovirals and Other Medicines: Lessons From Namibia.

Mabirizi D, Phulu B, Churfo W, Mwinga S, Mazibuko G, Sagwa E, Indongo L, Hafner T.

Glob Health Sci Pract. 2018 Dec 27;6(4):723-735. doi: 10.9745/GHSP-D-18-00157. Print 2018 Dec 27.


Renal function of MDR-TB patients treated with kanamycin regimens or concomitantly with antiretroviral agents.

Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Mengistu A, Mekonen TT, Leufkens HGM, Mantel-Teeuwisse AK.

Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1245-1250. doi: 10.5588/ijtld.16.0953.


An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia's public sector: Findings and therapeutic implications.

Kibuule D, Mubita M, Naikaku E, Kalemeera F, Godman BB, Sagwa E.

Int J Clin Pract. 2017 Feb;71(2). doi: 10.1111/ijcp.12918. Epub 2017 Jan 16.


Adverse events and patients' perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia.

Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK.

Patient Prefer Adherence. 2016 Nov 23;10:2369-2377. eCollection 2016.


Assessment of the World Health Organization's HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in Namibia.

Mutenda N, Bukowski A, Nitschke AM, Nakanyala T, Hamunime N, Mekonen T, Tjituka F, Mazibuko G, Mwinga S, Mabirizi D, Sagwa E, Indongo R, Dean N, Jordan MR, Hong SY.

PLoS One. 2016 Dec 1;11(12):e0166649. doi: 10.1371/journal.pone.0166649. eCollection 2016.


Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.

Sagwa EL, Souverein PC, Ribeiro I, Leufkens HG, Mantel-Teeuwisse AK.

Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):1-8. doi: 10.1002/pds.4125. Epub 2016 Nov 20.


Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis.

Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, Garrison LP Jr, Stergachis A.

Drug Saf. 2016 Sep;39(9):859-72. doi: 10.1007/s40264-016-0432-y.


Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia.

Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Baeten JM, Babigumira JB, Garrison LP, Stergachis A.

Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1052-60. doi: 10.1002/pds.4022. Epub 2016 May 2.


Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.

Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK.

BMC Pharmacol Toxicol. 2015 Dec 10;16:36. doi: 10.1186/s40360-015-0036-7.


Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study.

Sagwa EL, Mantel-Teeuwisse AK, Ruswa NC.

J Pharm Policy Pract. 2014 Oct 21;7(1):14. doi: 10.1186/2052-3211-7-14. eCollection 2014.


Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.

Sagwa E, Ruswa N, Musasa JP, Mantel-Teeuwisse AK.

Drug Saf. 2013 Nov;36(11):1087-96. doi: 10.1007/s40264-013-0091-1.


Antimicrobial sensitivity patterns of cerebrospinal fluid (CSF) isolates in Namibia: implications for empirical antibiotic treatment of meningitis.

Mengistu A, Gaeseb J, Uaaka G, Ndjavera C, Kambyambya K, Indongo L, Kalemeera F, Ntege C, Mabirizi D, Joshi MP, Sagwa E.

J Pharm Policy Pract. 2013 Jun 13;6:4. doi: 10.1186/2052-3211-6-4. eCollection 2013.


The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia.

Sagwa E, Mantel-Teeuwisse AK, Ruswa N, Musasa JP, Pal S, Dhliwayo P, van Wyk B.

South Med Rev. 2012 Jul;5(1):6-13. Epub 2012 Jul 23.


Records linkage of electronic databases for the assessment of adverse effects of antiretroviral therapy in sub-Saharan Africa.

Corbell C, Katjitae I, Mengistu A, Kalemeera F, Sagwa E, Mabirizi D, Lates J, Nwokike J, Fuller S, Stergachis A.

Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):407-14. doi: 10.1002/pds.2252. Epub 2011 Oct 19.


Supplemental Content

Support Center